Arrakis Therapeutics

OverviewSuggest Edit

Arrakis Therapeutics is a biopharmaceutical company which offers a drug discovery platform intended to target RNA. The Company develops an internal product pipeline of RNA-targeted small molecules focused on neurology, oncology, and rare genetic disorders. It offers scientific platforms, such as TRYST, MARS, PEARL-Seq, to identify tractable RNA targets, design drug molecules, and select candidates for clinical development. 
TypePrivate
Founded2015
HQWaltham, US
Websitearrakistx.com

Latest Updates

Employees (est.) (Sept 2020)67(+4%)
Cybersecurity ratingAMore

Key People/Management at Arrakis Therapeutics

Michael Gilman

Michael Gilman

Chief Executive Officer, Director
Katrine Bosley

Katrine Bosley

Chairman
Jennifer C. Petter

Jennifer C. Petter

Founder and Chief Scientific Officer
Jakob Loven

Jakob Loven

Director
Colleen Cuffaro

Colleen Cuffaro

Director
Raj Parekh

Raj Parekh

Director
Show more

Arrakis Therapeutics Office Locations

Arrakis Therapeutics has an office in Waltham
Waltham, US (HQ)
830 Winter St
Waltham, US
35 Gatehouse Dr
Show all (2)

Arrakis Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Arrakis Therapeutics total Funding

$113 m

Arrakis Therapeutics latest funding size

$75 m

Time since last funding

a year ago

Arrakis Therapeutics investors

Arrakis Therapeutics's latest funding round in April 2019 was reported to be $75 m. In total, Arrakis Therapeutics has raised $113 m
Show all financial metrics

Arrakis Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Arrakis Therapeutics Online and Social Media Presence

Embed Graph

Arrakis Therapeutics News and Updates

Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA

The Life Sciences team advised Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, on its $75 million Series B financing.read more

Arrakis Therapeutics Blogs

Arrakis Therapeutics Frequently Asked Questions

  • When was Arrakis Therapeutics founded?

    Arrakis Therapeutics was founded in 2015.

  • Who are Arrakis Therapeutics key executives?

    Arrakis Therapeutics's key executives are Michael Gilman, Katrine Bosley and Jennifer C. Petter.

  • How many employees does Arrakis Therapeutics have?

    Arrakis Therapeutics has 67 employees.

  • Who are Arrakis Therapeutics competitors?

    Competitors of Arrakis Therapeutics include Cure Genetics, Mustang Bio and Exicure.

  • Where is Arrakis Therapeutics headquarters?

    Arrakis Therapeutics headquarters is located at 830 Winter St, Waltham.

  • Where are Arrakis Therapeutics offices?

    Arrakis Therapeutics has an office in Waltham.

  • How many offices does Arrakis Therapeutics have?

    Arrakis Therapeutics has 2 offices.